Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 May;33(5):268-72.
doi: 10.1016/j.tips.2012.03.007. Epub 2012 Apr 13.

Structure-based drug screening for G-protein-coupled receptors

Brian K Shoichet  1 , Brian K Kobilka
Affiliations
Review

Structure-based drug screening for G-protein-coupled receptors

Brian K Shoichet et al. Trends Pharmacol Sci. 2012 May.

Abstract

G-protein-coupled receptors (GPCRs) represent a large family of signaling proteins that includes many therapeutic targets; however, progress in identifying new small molecule drugs has been disappointing. The past 4 years have seen remarkable progress in the structural biology of GPCRs, raising the possibility of applying structure-based approaches to GPCR drug discovery efforts. Of the various structure-based approaches that have been applied to soluble protein targets, such as proteases and kinases, in silico docking is among the most ready applicable to GPCRs. Early studies suggest that GPCR binding pockets are well suited to docking, and docking screens have identified potent and novel compounds for these targets. This review will focus on the current state of in silico docking for GPCRs.

PubMed Disclaimer

Figures

Figure 1
Figure 1
New inverse agonists against the β2AR structure discovered by molecular docking. Top row: four relatively potent ligands that resemble known chemotypes, with Ki values from 9 nM to 2 uM. Bottom row: two novel chemotypes, with Ki values of 1.1 and 3.3 uM.
Figure 2
Figure 2
Comparison of the binding pocket of the β2AR in the inactive (carbons in blue) and active (carbons in orange) conformations. The inverse agonist carazolol is shown with carbons in green. The largest difference is observed around Ser207 in transmembrane segment (TM) 5.
Figure 3
Figure 3
A 9 nM inverse agonist of β2AR discovered by docking: docked orientation (carbons in blue) superposed on the subsequent x-ray crystallographic result (carbons in green).[46]
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dixon RA, et al. Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature. 1986;321:75–79. - PubMed
    1. Kubo T, et al. Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature. 1986;323:411–416. - PubMed
    1. Fredriksson R, et al. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol. 2003;63:1256–1272. - PubMed
    1. Gribbon P, Sewing A. High-throughput drug discovery: what can we expect from HTS? Drug Discov Today. 2005;10:17–22. - PubMed
    1. Keiser MJ, et al. The chemical basis of pharmacology. Biochemistry. 2010;49:10267–10276. - PMC - PubMed

Publication types